查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703321

血友病 A 治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療類型、給藥途徑、配銷通路、地區和競爭細分，2020-2030 年預測

Hemophilia A Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球血友病 A 治療市場價值為 95.1 億美元，預計到 2030 年將達到約 136.8 億美元，預測期內年複合成長率(CAGR) 為 6.22%。該市場是更廣泛的醫藥和醫療保健領域的重要組成部分，滿足了被診斷患有血友病 A（一種因缺乏凝血因子 VIII 而導致的罕見遺傳性疾病）的個人的特定需求。

市場概覽
預測期 2026-2030
2024年市場規模 95.1億美元
2030年市場規模 136.8億美元
2025-2030 年複合年成長率 6.22%
成長最快的領域 網路藥局
最大的市場 北美洲

該市場涵蓋了全面的治療解決方案，旨在預防和管理與血友病 A 相關的可能危及生命的併發症。主要成長動力之一是該疾病在全球範圍內的盛行率上升，以及診斷能力的提高。人們的認知不斷提高，基因和分子診斷技術也不斷進步，使得更多的人得到了準確的診斷，從而推動了對先進治療方案的需求。

傳統的治療方式主要依賴靜脈注射來自血漿或重組來源的凝血因子 VIII。然而，市場正在經歷重大轉型，越來越重視下一代療法，特別是基因療法和非因子替代療法。基因療法尤其具有變革潛力，它針對的是疾病的根本遺傳原因，提供了長期甚至治癒結果的可能性。

關鍵市場促進因素

盛行率上升，診斷水準提高

主要市場挑戰

治療費用高昂

主要市場趨勢

基因治療的出現

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球血友病A治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（因子替代療法、非因子替代療法、基因療法）
    • 依給藥途徑（靜脈注射、口服、鼻腔注射）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按治療類型
    • 依給藥途徑
    • 按配銷通路
    • 按地區

第5章：亞太地區血友病A治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按治療類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲血友病A治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美血友病A治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
    • 治療類型
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲血友病 A 治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章：中東和非洲血友病A治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球血友病 A 治療市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Takeda Pharmaceutical Company Limited
  • Sanofi Corporation
  • Genentech USA, Inc.
  • Novo Nordisk
  • Pfizer Inc.
  • CSL Behring LLC.
  • Grifols
  • Sagent Pharmaceuticals
  • Octapharma USA Inc.
  • UBI Pharma Inc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16872

Global Hemophilia A Treatment Market was valued at USD 9.51 billion in 2024 and is projected to reach approximately USD 13.68 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.22% during the forecast period. This market forms a vital part of the broader pharmaceutical and healthcare landscape, addressing the specific needs of individuals diagnosed with Hemophilia A-a rare genetic disorder resulting from a deficiency in clotting factor VIII.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 9.51 Billion
Market Size 2030USD 13.68 Billion
CAGR 2025-20306.22%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

The market encompasses a comprehensive range of therapeutic solutions aimed at preventing and managing the potentially life-threatening complications associated with Hemophilia A. One of the key growth drivers is the rising global prevalence of the disorder, coupled with increasing diagnostic capabilities. Enhanced awareness and improvements in genetic and molecular diagnostics have led to a greater number of individuals being accurately diagnosed, thereby fueling demand for advanced treatment options.

Traditional treatment modalities have predominantly relied on intravenous administration of clotting factor VIII, derived either from plasma or recombinant sources. However, the market is undergoing a significant transformation, with growing emphasis on next-generation therapies-notably gene therapy and non-factor replacement treatments. Gene therapy, in particular, holds transformative potential by targeting the root genetic cause of the disease, offering the possibility of long-term or even curative outcomes.

Key Market Drivers

Rising Prevalence and Improved Diagnosis

The growth of the Hemophilia A Treatment Market is closely linked to the increasing prevalence of the disorder and advancements in diagnostic methodologies. Hemophilia A continues to pose a considerable public health burden. According to the World Federation of Hemophilia (WFH), an estimated 179,703 individuals worldwide had been identified with Hemophilia A as of 2023. This increase is largely attributable to greater public awareness, improved diagnostic tools, and expanded genetic testing.

The WFH has outlined a five-year strategic objective (2020-2025) to increase global diagnosis by 60,000 cases, reflecting a 25% growth. Enhanced diagnostic capabilities, including molecular and genetic testing, now allow for earlier and more accurate detection of the disorder. Early diagnosis enables personalized treatment approaches, thereby improving patient outcomes and driving innovation in the development of gene-targeted therapies.

In a landmark development, the U.S. Food and Drug Administration (FDA) approved Roctavian in June 2023-the first AAV-based gene therapy for adults with severe Hemophilia A-marking a major milestone in therapeutic advancements.

Key Market Challenges

High Cost of Treatment

The high cost of treatment remains a significant barrier to widespread adoption and accessibility within the Hemophilia A Treatment Market. Managing the disorder requires lifelong therapeutic intervention, placing a substantial financial burden on both patients and healthcare systems.

One of the principal cost drivers is factor replacement therapy, which involves complex and costly manufacturing processes. Patients often require frequent infusions-sometimes multiple times per week-exacerbating the financial strain. While extended half-life products offer the benefit of reduced infusion frequency, their higher price point offsets potential savings.

Gene therapy, although promising, also introduces new cost challenges. The production of viral vectors and genetic manipulation processes involved in gene therapy are resource-intensive, resulting in exceptionally high treatment costs. These economic factors present a major constraint on broader market accessibility and adoption.

Key Market Trends

The Emergence of Gene Therapy

Gene therapy is revolutionizing the treatment paradigm for Hemophilia A. By introducing functional factor VIII genes into the patient's cells, gene therapy targets the genetic basis of the disorder and offers a potential long-term or curative solution.

This therapeutic approach eliminates or significantly reduces the need for regular factor infusions, thereby improving patients' quality of life and easing the treatment burden. Gene therapy has demonstrated promising results in clinical trials, showing the ability to sustain elevated levels of factor VIII and reduce the incidence of spontaneous bleeding episodes.

Furthermore, gene therapy addresses several of the chronic challenges associated with traditional treatments, such as inhibitor development and treatment non-compliance. Its one-time or infrequent dosing regimen enhances patient adherence and convenience, making it a game-changing development in the market.

Key Market Players

  • Takeda Pharmaceutical Company Limited
  • Sanofi Corporation
  • Genentech USA, Inc.
  • Novo Nordisk
  • Pfizer Inc.
  • CSL Behring LLC.
  • Grifols
  • Sagent Pharmaceuticals
  • Octapharma USA Inc.
  • UBI Pharma Inc.

Report Scope:

In this report, the Global Hemophilia A Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemophilia A Treatment Market, By Treatment Type:

  • Factor Replacement Therapy
  • Non-Factor Replacement Therapies
  • Gene Therapy

Hemophilia A Treatment Market, By Route of Administration:

  • Intravenous
  • Oral
  • Nasal

Hemophilia A Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hemophilia A Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemophilia A Treatment Market.

Available Customizations:

Global Hemophilia A Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hemophilia A Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment Type (Factor Replacement Therapy, Non-Factor Replacement Therapies, Gene Therapy)
    • 4.2.2. By Route of Administration (Intravenous, Oral, Nasal)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Treatment Type
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Hemophilia A Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type
    • 5.2.2. By Route of Administration
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Hemophilia A Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Hemophilia A Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment Type
        • 5.3.2.2.2. By Route of Administration
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Hemophilia A Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment Type
        • 5.3.3.2.2. By Route of Administration
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Hemophilia A Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment Type
        • 5.3.4.2.2. By Route of Administration
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Hemophilia A Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment Type
        • 5.3.5.2.2. By Route of Administration
        • 5.3.5.2.3. By Distribution Channel

6. Europe Hemophilia A Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Hemophilia A Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Hemophilia A Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Hemophilia A Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Hemophilia A Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Hemophilia A Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. North America Hemophilia A Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. Treatment Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Hemophilia A Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Hemophilia A Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Hemophilia A Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. South America Hemophilia A Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Hemophilia A Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Hemophilia A Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Hemophilia A Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Hemophilia A Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Hemophilia A Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Hemophilia A Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Hemophilia A Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Hemophilia A Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Takeda Pharmaceutical Company Limited
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Sanofi Corporation
  • 14.3. Genentech USA, Inc.
  • 14.4. Novo Nordisk
  • 14.5. Pfizer Inc.
  • 14.6. CSL Behring LLC.
  • 14.7. Grifols
  • 14.8. Sagent Pharmaceuticals
  • 14.9. Octapharma USA Inc.
  • 14.10. UBI Pharma Inc

15. Strategic Recommendations

16. About Us & Disclaimer